Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp fastacting insulin aspart for the treatment of diabetes

Bagsvrd Denmark 11 November 2016 Novo Nordisk today announced that the Committee for Medicinal Products for Human Use CHMP under the European Medicines Agency EMA adopted a positive opinion for the u…
Read the full story: Bioportfolio Latest News